Paper41396112
Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome.
Uslu E and 6 others. Sarcoidosis Vasc Diffuse Lung Dis, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome. Papers, record 41396112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41396112
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29625968 | 2018 update of the EULAR recommendations for the management of Behçet's syndrome. | Ann Rheum Dis | 2018 | https://conductscience.org/library/papers/29625968 | PubMed |
| 2 | 7923750 | Cyclosporine: mechanisms of action and toxicity. | Cleve Clin J Med | 1994 | https://conductscience.org/library/papers/7923750 | PubMed |
| 3 | 31976619 | Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature. | Int J Rheum Dis | 2020 | https://conductscience.org/library/papers/31976619 | PubMed |
| 4 | 10528040 | Behçet's disease. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10528040 | PubMed |
| 5 | 31139195 | Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils. | Front Immunol | 2019 | https://conductscience.org/library/papers/31139195 | PubMed |
| 6 | 22210555 | Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. | Medicine (Baltimore) | 2012 | https://conductscience.org/library/papers/22210555 | PubMed |
| 7 | 27886800 | Behçet's disease: How to diagnose and treat vascular involvement. | Best Pract Res Clin Rheumatol | 2016 | https://conductscience.org/library/papers/27886800 | PubMed |
| 8 | 9125262 | Azathioprine in Behcet's syndrome: effects on long-term prognosis. | Arthritis Rheum | 1997 | https://conductscience.org/library/papers/9125262 | PubMed |
| 9 | 37385325 | Infliximab for vascular involvement in Behçet's syndrome. | Clin Immunol | 2023 | https://conductscience.org/library/papers/37385325 | PubMed |
| 10 | 10410282 | Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A. | Clin Exp Rheumatol | 1999 | https://conductscience.org/library/papers/10410282 | PubMed |
| 11 | 2356556 | Cyclosporin treatment in rapidly progressive pulmonary thromboembolic Behçet's disease. | Thorax | 1990 | https://conductscience.org/library/papers/2356556 | PubMed |
| 12 | 10759951 | Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. | Histopathology | 2000 | https://conductscience.org/library/papers/10759951 | PubMed |
| 13 | 21699532 | Mycophenolate sodium in the treatment of mucocutaneous Behcet's diseases. | Int J Dermatol | 2011 | https://conductscience.org/library/papers/21699532 | PubMed |
| 14 | 12544711 | The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. | Medicine (Baltimore) | 2003 | https://conductscience.org/library/papers/12544711 | PubMed |
| 15 | 21968239 | Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. | Clin Exp Rheumatol | 2011 | https://conductscience.org/library/papers/21968239 | PubMed |
| 16 | 11752821 | Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. | Dermatology | 2001 | https://conductscience.org/library/papers/11752821 | PubMed |
| 17 | 27310969 | Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. | Medicine (Baltimore) | 2016 | https://conductscience.org/library/papers/27310969 | PubMed |
| 18 | 29631062 | Behçet's disease: New insights into pathophysiology, clinical features and treatment options. | Autoimmun Rev | 2018 | https://conductscience.org/library/papers/29631062 | PubMed |
| 19 | 14673387 | Behçet syndrome. | Curr Opin Rheumatol | 2004 | https://conductscience.org/library/papers/14673387 | PubMed |
| 20 | 26190564 | Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment. | Semin Arthritis Rheum | 2015 | https://conductscience.org/library/papers/26190564 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41396112
GET https://conductscience.org/api/papers/v1/41396112/references?page=2